Legal probes surface: Social media conversations focus on shareholder investigations into Insulet's directors and officers for alleged fiduciary duty breaches tied to share acquisitions before February 2025. Observers reference an FDA Class I recall and a 47% stock decline over the past year as key factors heightening scrutiny. Valuation metrics continue to draw attention despite these headwinds.
Omnipod advancements noted: Posts highlight the Omnipod 5 automated insulin delivery system's role in improving patient outcomes for diabetes management starting from age two. Real-world user experiences underscore its utility in challenging environments like extreme heat and physical activity. The device remains a central topic in broader digital health discussions.
Stock visibility rises: Insulet appears frequently in trading scans alongside peers in healthcare technology, signaling ongoing market monitoring. Commentary balances product strengths against persistent legal and regulatory risks. Sentiment stays measured as participants weigh these elements.
Note: This discussion summary was generated from an AI condensation of post data.
Insulet Corporation Insider Trading Activity
Insulet Corporation insiders have traded $PODD stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:
- ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
- MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
- ELIZABETH H WEATHERMAN purchased 3,450 shares for an estimated $497,489
- TIMOTHY C. STONESIFER purchased 2,790 shares for an estimated $400,392
- LUCIANA BORIO sold 418 shares for an estimated $59,886
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive PODD Data Alerts
Get market-moving data, filings, and signals for PODD in real time.
Sign Up
Insulet Corporation Revenue
Insulet Corporation had revenues of $761.7M in Q1 2026. This is an increase of 33.87% from the same period in the prior year.
You can track PODD financials on Quiver Quantitative's PODD stock page.
You can access data on PODD stock through the Quiver Quantitative API.
Insulet Corporation Congressional Stock Trading
Members of Congress have traded $PODD stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PODD stock by members of Congress over the last 6 months:
- SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Insulet Corporation Hedge Fund Activity
We have seen 365 institutional investors add shares of Insulet Corporation stock to their portfolio, and 408 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 2,739,416 shares (-62.1%) from their portfolio in Q1 2026, for an estimated $574,839,053
- FMR LLC removed 2,350,642 shares (-37.2%) from their portfolio in Q1 2026, for an estimated $493,258,717
- AQR CAPITAL MANAGEMENT LLC added 1,139,609 shares (+248.2%) to their portfolio in Q1 2026, for an estimated $239,135,552
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,011,369 shares (+462.7%) to their portfolio in Q1 2026, for an estimated $212,225,670
- JUPITER ASSET MANAGEMENT LTD added 475,438 shares (+202.8%) to their portfolio in Q1 2026, for an estimated $99,765,909
- SOLEUS CAPITAL MANAGEMENT, L.P. added 412,500 shares (+275.0%) to their portfolio in Q1 2026, for an estimated $86,559,000
- TWO SIGMA INVESTMENTS, LP added 395,627 shares (+107.9%) to their portfolio in Q1 2026, for an estimated $83,018,369
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Insulet Corporation Analyst Ratings
Wall Street analysts have issued reports on $PODD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 05/20/2026
- JP Morgan issued a "Overweight" rating on 05/07/2026
To track analyst ratings and price targets for Insulet Corporation, check out Quiver Quantitative's $PODD forecast page.
Insulet Corporation Price Targets
Multiple analysts have issued price targets for $PODD recently. We have seen 17 analysts offer price targets for $PODD in the last 6 months, with a median target of $220.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $172.0 on 07/08/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $180.0 on 07/06/2026
- Kieran Ryan from Deutsche Bank set a target price of $190.0 on 06/23/2026
- Richard Newitter from Truist Securities set a target price of $219.0 on 06/12/2026
- Marie Thibault from BTIG set a target price of $235.0 on 05/27/2026
- Shagun Singh from RBC Capital set a target price of $280.0 on 05/27/2026
- Travis Steed from B of A Securities set a target price of $208.0 on 05/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Insulet Corporation Stock (PODD) Opinions on Legal Investigations and Omnipod Advancements
Legal probes surface: Social media conversations focus on shareholder investigations into Insulet's directors and officers for alleged fiduciary duty breaches tied to share acquisitions before February 2025. Observers reference an FDA Class I recall and a 47% stock decline over the past year as key factors heightening scrutiny. Valuation metrics continue to draw attention despite these headwinds.
Omnipod advancements noted: Posts highlight the Omnipod 5 automated insulin delivery system's role in improving patient outcomes for diabetes management starting from age two. Real-world user experiences underscore its utility in challenging environments like extreme heat and physical activity. The device remains a central topic in broader digital health discussions.
Stock visibility rises: Insulet appears frequently in trading scans alongside peers in healthcare technology, signaling ongoing market monitoring. Commentary balances product strengths against persistent legal and regulatory risks. Sentiment stays measured as participants weigh these elements.
Note: This discussion summary was generated from an AI condensation of post data.
Insulet Corporation Insider Trading Activity
Insulet Corporation insiders have traded $PODD stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Insulet Corporation Revenue
Insulet Corporation had revenues of $761.7M in Q1 2026. This is an increase of 33.87% from the same period in the prior year.
You can track PODD financials on Quiver Quantitative's PODD stock page.
You can access data on PODD stock through the Quiver Quantitative API.
Insulet Corporation Congressional Stock Trading
Members of Congress have traded $PODD stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PODD stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Insulet Corporation Hedge Fund Activity
We have seen 365 institutional investors add shares of Insulet Corporation stock to their portfolio, and 408 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Insulet Corporation Analyst Ratings
Wall Street analysts have issued reports on $PODD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for Insulet Corporation, check out Quiver Quantitative's $PODD forecast page.
Insulet Corporation Price Targets
Multiple analysts have issued price targets for $PODD recently. We have seen 17 analysts offer price targets for $PODD in the last 6 months, with a median target of $220.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »